JP2014507446A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507446A5 JP2014507446A5 JP2013555647A JP2013555647A JP2014507446A5 JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5 JP 2013555647 A JP2013555647 A JP 2013555647A JP 2013555647 A JP2013555647 A JP 2013555647A JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- following
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 CC(CCN1c(cnc(N2CC*(C)(COP(O)(O)=O)CC2)c2)c2-c2c(C)cccc2)(C1=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound CC(CCN1c(cnc(N2CC*(C)(COP(O)(O)=O)CC2)c2)c2-c2c(C)cccc2)(C1=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564537P | 2011-11-29 | 2011-11-29 | |
| US61/564,537 | 2011-11-29 | ||
| US13/478,361 | 2012-05-23 | ||
| US13/478,361 US8426450B1 (en) | 2011-11-29 | 2012-05-23 | Substituted 4-phenyl pyridines having anti-emetic effect |
| PCT/US2012/066778 WO2013082102A1 (en) | 2011-11-29 | 2012-11-28 | Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014210716A Division JP6023146B2 (ja) | 2011-11-29 | 2014-10-15 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507446A JP2014507446A (ja) | 2014-03-27 |
| JP2014507446A5 true JP2014507446A5 (show.php) | 2014-06-19 |
| JP5635708B2 JP5635708B2 (ja) | 2014-12-03 |
Family
ID=48094815
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555647A Active JP5635708B2 (ja) | 2011-11-29 | 2012-11-28 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
| JP2014210716A Active JP6023146B2 (ja) | 2011-11-29 | 2014-10-15 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
| JP2016034427A Active JP6074083B2 (ja) | 2011-11-29 | 2016-02-25 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014210716A Active JP6023146B2 (ja) | 2011-11-29 | 2014-10-15 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
| JP2016034427A Active JP6074083B2 (ja) | 2011-11-29 | 2016-02-25 | Ｎｋ−１レセプター関連疾患の治療のための置換４−フェニル−ピリジン |
Country Status (50)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2808630A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| AU2011338428B2 (en) | 2010-12-07 | 2015-05-21 | Allison Transmission, Inc. | Energy storage system for hybrid electric vehicle |
| WO2012176061A1 (en) | 2011-06-22 | 2012-12-27 | Purdue Pharma L.P. | Trpv1 antagonists including dihydroxy substituent and uses thereof |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| ES2671418T3 (es) | 2013-11-08 | 2018-06-06 | Kissei Pharmaceutical Co., Ltd. | Derivado de carboximetilpiperidina |
| WO2015171489A1 (en) * | 2014-05-05 | 2015-11-12 | Apicore Us Llc | Methods of making netupitant and intermediates thereof |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| TW201613888A (en) * | 2014-09-26 | 2016-04-16 | Helsinn Healthcare Sa | Crystalline forms of an NK-1 antagonist |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | 成都欣捷高新技术开发有限公司 | 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法 |
| US10005803B2 (en) * | 2015-10-06 | 2018-06-26 | Helsinn Healthcare Sa | Crystalline forms of fosnetupitant |
| CN106892864A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种奈妥皮坦游离碱的晶型a及其制备方法 |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR102459416B1 (ko) * | 2016-06-06 | 2022-10-27 | 헬신 헬쓰케어 에스.에이. | 포스네투피탄트의 생리학적으로 균형잡힌 주사가능 제제 |
| HRP20211683T1 (hr) | 2016-09-30 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| CN108619525B (zh) * | 2017-03-15 | 2020-12-29 | 和龙 | 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR20250069704A (ko) | 2017-06-30 | 2025-05-19 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| CN107698500A (zh) * | 2017-10-17 | 2018-02-16 | 扬子江药业集团四川海蓉药业有限公司 | 一种奈妥匹坦的制备方法 |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| WO2019138162A1 (en) * | 2018-01-12 | 2019-07-18 | Orion Corporation | Palonosetron for the treatment or prevention of nausea and vomiting |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| JP7156154B2 (ja) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | 培地処理システム及び培地処理方法 |
| CN112174881B (zh) * | 2019-07-04 | 2022-06-21 | 上海森辉医药有限公司 | 一种奈妥匹坦的衍生物及其制备方法 |
| CN112778370B (zh) * | 2019-11-06 | 2025-09-26 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种制备福奈妥匹坦的方法 |
| AU2021246889A1 (en) | 2020-04-03 | 2022-10-13 | Nerre Therapeutics Limited | An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS) |
| MX2022014901A (es) | 2020-06-02 | 2023-01-18 | Nerre Therapeutics Ltd | Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones. |
| US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
| WO2025036703A1 (en) | 2023-08-13 | 2025-02-20 | Helsinn Healthcare Sa | Fosnetupitant for administration via intravenous bolus |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010033811A (ko) | 1997-12-31 | 2001-04-25 | 토마스 안 빅토리아 | 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법 |
| DK1394150T3 (da) | 1999-02-24 | 2011-03-21 | Hoffmann La Roche | 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister |
| SI1103545T1 (en) * | 1999-11-29 | 2004-02-29 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| US6303790B1 (en) | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| US6362172B2 (en) * | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
| NZ523273A (en) | 2000-07-14 | 2004-08-27 | F | N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
| ES2272408T3 (es) | 2000-12-14 | 2007-05-01 | F. Hoffmann-La Roche Ag | Matriz lipidica autoemulsificante (selm). |
| US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| EP1863767B1 (en) * | 2005-03-23 | 2009-03-11 | F. Hoffmann-Roche AG | Metabolites for nk-i antagonists for emesis |
| CN101282979B (zh) * | 2005-09-13 | 2011-09-21 | 卫材R&D管理有限公司 | 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法 |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| UA108077C2 (xx) * | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
| LT2722045T (lt) * | 2009-11-18 | 2016-09-26 | Helsinn Healthcare Sa | Kompozicija skirta gydyti centralizuotai kontroliuojamą pykinimą ir vėmimą |
| AU2010339689B2 (en) * | 2010-01-07 | 2015-02-19 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| HRP20160478T1 (hr) * | 2010-12-02 | 2016-07-01 | The University Of Kansas | Prolijekovi 6-cikloheksil-1-hidroksi-4-metilpiridin-2-(1h)-ona i njihovi derivati |
| US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| US8952169B2 (en) | 2012-05-22 | 2015-02-10 | Xenon Pharmaceuticals Inc. | N-substituted benzamides and methods of use thereof |
-
2012
- 2012-05-23 US US13/478,361 patent/US8426450B1/en active Active
- 2012-11-19 JO JOP/2012/0348A patent/JO3202B1/ar active
- 2012-11-28 PT PT127985497T patent/PT2785706T/pt unknown
- 2012-11-28 CN CN202110222556.5A patent/CN112979543B/zh active Active
- 2012-11-28 LT LTEP12798549.7T patent/LT2785706T/lt unknown
- 2012-11-28 PE PE2014000630A patent/PE20141421A1/es active IP Right Grant
- 2012-11-28 MY MYPI2014001505A patent/MY165514A/en unknown
- 2012-11-28 HR HRP20161708TT patent/HRP20161708T1/hr unknown
- 2012-11-28 BR BR112014012878-2A patent/BR112014012878B1/pt active IP Right Grant
- 2012-11-28 MD MDA20140059A patent/MD4539C1/ro active IP Right Grant
- 2012-11-28 WO PCT/US2012/066778 patent/WO2013082102A1/en not_active Ceased
- 2012-11-28 IN IN4907CHN2014 patent/IN2014CN04907A/en unknown
- 2012-11-28 KR KR1020147017431A patent/KR101979050B1/ko active Active
- 2012-11-28 CN CN202110222524.5A patent/CN112961104A/zh active Pending
- 2012-11-28 EA EA201400624A patent/EA026553B1/ru unknown
- 2012-11-28 ME MEP-2016-283A patent/ME02561B/me unknown
- 2012-11-28 CN CN201710324776.2A patent/CN106986822B/zh active Active
- 2012-11-28 SG SG11201402044XA patent/SG11201402044XA/en unknown
- 2012-11-28 AU AU2012346133A patent/AU2012346133B2/en active Active
- 2012-11-28 JP JP2013555647A patent/JP5635708B2/ja active Active
- 2012-11-28 CN CN201280058800.8A patent/CN104053652A/zh active Pending
- 2012-11-28 DK DK12798549.7T patent/DK2785706T3/en active
- 2012-11-28 EP EP12798549.7A patent/EP2785706B1/en active Active
- 2012-11-28 SI SI201230810A patent/SI2785706T1/sl unknown
- 2012-11-28 CA CA2850644A patent/CA2850644C/en active Active
- 2012-11-28 SM SM20160467T patent/SMT201600467T1/it unknown
- 2012-11-28 AP AP2014007729A patent/AP2014007729A0/xx unknown
- 2012-11-28 CN CN201610957278.7A patent/CN106518924B/zh active Active
- 2012-11-28 HU HUE12798549A patent/HUE032288T2/hu unknown
- 2012-11-28 CN CN202010607408.0A patent/CN111662330B/zh active Active
- 2012-11-28 ES ES12798549.7T patent/ES2603958T3/es active Active
- 2012-11-28 UA UAA201407175A patent/UA115136C2/uk unknown
- 2012-11-28 UY UY0001034472A patent/UY34472A/es active IP Right Grant
- 2012-11-28 MX MX2014006423A patent/MX2014006423A/es unknown
- 2012-11-28 GE GEAP201213508A patent/GEP201706695B/en unknown
- 2012-11-28 RS RS20161103A patent/RS55448B1/sr unknown
- 2012-11-28 PL PL12798549T patent/PL2785706T3/pl unknown
- 2012-11-29 AR ARP120104473A patent/AR089019A1/es active IP Right Grant
- 2012-11-29 TW TW101144681A patent/TWI638806B/zh active
-
2013
- 2013-04-17 US US13/864,381 patent/US8895586B2/en active Active
-
2014
- 2014-04-18 TN TNP2014000165A patent/TN2014000165A1/en unknown
- 2014-05-13 NI NI201400043A patent/NI201400043A/es unknown
- 2014-05-15 CL CL2014001280A patent/CL2014001280A1/es unknown
- 2014-05-26 GT GT201400102A patent/GT201400102A/es unknown
- 2014-05-28 IL IL232859A patent/IL232859B/en active IP Right Grant
- 2014-05-28 PH PH12014501199A patent/PH12014501199B1/en unknown
- 2014-05-28 DO DO2014000115A patent/DOP2014000115A/es unknown
- 2014-06-05 EC ECIEPI20143642A patent/ECSP14003642A/es unknown
- 2014-06-20 CO CO14134660A patent/CO6990728A2/es unknown
- 2014-06-25 MA MA37152A patent/MA35836B1/fr unknown
- 2014-06-27 ZA ZA2014/04787A patent/ZA201404787B/en unknown
- 2014-06-27 CR CR20140312A patent/CR20140312A/es unknown
- 2014-10-15 JP JP2014210716A patent/JP6023146B2/ja active Active
-
2016
- 2016-02-25 JP JP2016034427A patent/JP6074083B2/ja active Active
- 2016-06-28 US US15/194,984 patent/US9908907B2/en active Active
- 2016-12-09 CY CY20161101278T patent/CY1118416T1/el unknown
- 2016-12-22 SM SM201600467T patent/SMT201600467B/it unknown
-
2018
- 2018-01-18 US US15/874,325 patent/US10208073B2/en active Active
- 2018-12-21 US US16/228,835 patent/US10717721B2/en active Active
-
2020
- 2020-06-08 US US16/896,135 patent/US11312698B2/en active Active
- 2020-06-16 LT LTPA2020510C patent/LTC2785706I2/lt unknown
- 2020-06-18 NL NL301047C patent/NL301047I2/nl unknown
- 2020-06-24 FI FIC20200022C patent/FIC20200022I1/fi unknown
- 2020-07-03 FR FR20C1029C patent/FR20C1029I2/fr active Active
- 2020-07-03 CY CY2020017C patent/CY2020017I1/el unknown
- 2020-08-18 HU HUS2000032C patent/HUS2000032I1/hu unknown
-
2022
- 2022-03-21 US US17/699,522 patent/US12071421B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507446A5 (show.php) | ||
| JP2013014622A5 (show.php) | ||
| JP2012107057A5 (show.php) | ||
| JP2017509667A5 (show.php) | ||
| JP2009545527A5 (show.php) | ||
| JP2016518337A5 (show.php) | ||
| JP2015078230A5 (show.php) | ||
| JP2014221779A5 (show.php) | ||
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| JP2012255026A5 (show.php) | ||
| JP2013525444A5 (show.php) | ||
| JP2018521020A5 (show.php) | ||
| JP2012126725A5 (show.php) | ||
| JP2013509429A5 (show.php) | ||
| JP2015501783A5 (show.php) | ||
| JP2014515013A5 (show.php) | ||
| JP2011105738A5 (show.php) | ||
| JP2015528502A5 (show.php) | ||
| JP2013032389A5 (show.php) | ||
| JP2013532687A5 (show.php) | ||
| JP2017537066A5 (show.php) | ||
| JP2013522326A5 (show.php) | ||
| EP2833721A4 (en) | NICKEL OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| JP2014530840A5 (show.php) |